CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
CERo Therapeutics (Nasdaq: CERO) presented preclinical data showing its lead compound CER-1236 effectively kills ovarian cancer cells without toxicity in animal models. The data, presented at the SITC 2024 Conference, demonstrated that CER-1236 targets the immune receptor TIM-4-L in ovarian cancer cell lines. The study revealed that after introducing CER-1236, TIM-4-L expression increased, leading to cancer cell death while sparing healthy cells. The compound's specificity to TIM-L-4 and absence of clinical toxicity suggest potential applications in ovarian cancer treatment. The company plans to pursue Orphan designation during clinical development.
CERo Therapeutics (Nasdaq: CERO) ha presentato dati preclinici che mostrano come il suo composto principale CER-1236 uccida efficacemente le cellule del cancro ovarico senza tossicità nei modelli animali. I dati, presentati alla Conferenza SITC 2024, hanno dimostrato che CER-1236 colpisce il recettore immunitario TIM-4-L nelle linee cellulari del cancro ovarico. Lo studio ha rivelato che dopo l'introduzione di CER-1236, l'espressione di TIM-4-L è aumentata, portando alla morte delle cellule tumorali, risparmiando al contempo le cellule sane. La specificità del composto per TIM-4-L e l'assenza di tossicità clinica suggeriscono applicazioni potenziali nel trattamento del cancro ovarico. L'azienda prevede di perseguire la designazione Orphan durante lo sviluppo clinico.
CERo Therapeutics (Nasdaq: CERO) presentó datos preclínicos que muestran que su compuesto líder CER-1236 mata efectivamente las células del cáncer de ovario sin toxicidad en modelos animales. Los datos, presentados en la Conferencia SITC 2024, demostraron que CER-1236 se dirige al receptor inmunitario TIM-4-L en líneas celulares de cáncer de ovario. El estudio reveló que después de introducir CER-1236, la expresión de TIM-4-L aumentó, lo que llevó a la muerte de las células cancerosas, mientras se preservaban las células sanas. La especificidad del compuesto por TIM-4-L y la ausencia de toxicidad clínica sugieren aplicaciones potenciales en el tratamiento del cáncer de ovario. La empresa planea solicitar la designación de Huérfano durante el desarrollo clínico.
CERo Therapeutics (Nasdaq: CERO)는 주요 화합물 CER-1236이 동물 모델에서 독성 없이 난소암 세포를 효과적으로 죽인다는 전임상 데이터를 발표했습니다. SITC 2024 컨퍼런스에서 발표된 이 데이터는 CER-1236이 난소암 세포주에서 면역 수용체 TIM-4-L을 표적으로 한다는 것을 보여주었습니다. 연구 결과 CER-1236을 도입한 후 TIM-4-L의 발현이 증가하여 암 세포의 사멸을 초래하면서 건강한 세포는 보존되었습니다. TIM-4-L에 대한 화합물의 특이성과 임상 독성이 없음을 감안할 때, 난소암 치료에 대한 잠재적 응용 가능성이 제시됩니다. 회사는 임상 개발 중 고아 지정 신청을 계획하고 있습니다.
CERo Therapeutics (Nasdaq: CERO) a présenté des données précliniques montrant que son composé principal CER-1236 tue efficacement les cellules du cancer de l'ovaire sans toxicité dans des modèles animaux. Les données, présentées lors de la Conférence SITC 2024, ont démontré que CER-1236 cible le récepteur immunitaire TIM-4-L dans des lignées cellulaires de cancer de l'ovaire. L'étude a révélé qu'après l'introduction de CER-1236, l'expression de TIM-4-L a augmenté, entraînant la mort des cellules cancéreuses tout en épargnant les cellules saines. La spécificité du composé pour TIM-4-L et l'absence de toxicité clinique suggèrent des applications potentielles dans le traitement du cancer de l'ovaire. L'entreprise prévoit de demander une désignation de médicament orphelin pendant le développement clinique.
CERo Therapeutics (Nasdaq: CERO) präsentierte präklinische Daten, die zeigen, dass die Hauptverbindung CER-1236 effektiv Eierstockkrebszellen ohne Toxizität in Tiermodellen abtötet. Die Daten, die auf der SITC 2024-Konferenz präsentiert wurden, zeigten, dass CER-1236 den Immunrezeptor TIM-4-L in Eierstockkrebs-Zelllinien anvisiert. Die Studie ergab, dass nach der Einführung von CER-1236 die TIM-4-L-Expression zunahm, was zum Zelltod der Krebszellen führte, während gesunde Zellen geschont wurden. Die Spezifität der Verbindung für TIM-4-L und das Fehlen klinischer Toxizität deuten auf potenzielle Anwendungen in der Behandlung von Eierstockkrebs hin. Das Unternehmen plant, während der klinischen Entwicklung eine Waisen-Designation zu verfolgen.
- Successful preclinical results showing cancer cell death without toxicity
- Demonstrated specificity to target receptor TIM-L-4
- Potential for multiple cancer applications beyond AML
- Possibility for Orphan drug designation
- Still in preclinical stage, not yet in clinical trials
- Timeline for clinical trials not specified
Insights
The preclinical data for CER-1236 reveals promising potential in ovarian cancer treatment through a novel mechanism targeting TIM-4-L receptors. The compound's ability to selectively kill cancer cells while sparing healthy tissue represents a significant technical achievement in the field of engineered T cell therapeutics.
This dual-indication potential (both AML and ovarian cancer) significantly expands the drug's market opportunity. The lack of toxicity is particularly noteworthy, as current chemotherapy options often come with severe side effects. The potential for Orphan Drug designation in ovarian cancer could provide additional market exclusivity and development incentives.
However, investors should note that these are still preclinical results and success in animal models doesn't guarantee clinical efficacy. The timeline to potential commercialization remains lengthy, with clinical trials yet to begin.
Data presented as part of a poster at the SITC 2024 Conference
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ovarian cancer cells in preclinical models with no indications of toxicity in animal models. The data were presented in a poster at the Society for Immunology of Cancer (SITC) 2024 conference held in Houston November 6-10, 2024.
Interim CEO Chris Ehrlich commented, “We have long contended that CER-1236 has application in multiple cancer types. While we await the opportunity to introduce our compound into the clinic for AML, we continue to see other models in which there is utility and minimal-to-no toxicity. These data are of particular interest as the Company plans to apply for Orphan designation at the appropriate time in clinical development. Regardless, these data are further confirmation that our approach has enormous potential to go beyond some of the limitations of current chemotherapy approaches.”
The study, titled, “TIM-4 Expression on Ovarian Cancer Samples can be Targeted by Engineered Chimeric Engulfment Receptor T cells without Toxicity,” investigators assessed CER-1236 on the immune receptor TIM-4-L in ovarian cancer cell lines. Results demonstrated that following the introduction of CER-1236 on these cell lines, TIM-4-L increased, which then responded with the killing of the cancer cells, but with no observed toxicity to healthy cells. The study further showed CER-1236 specificity to TIM-L-4, which investigators concluded that combined with the lack of association with clinically relevant toxicity, may make the compound an attractive option for treating ovarian cancer.
About CERo Therapeutics, Inc.
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor (“CAR-T”) cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in early 2025 for hematological malignancies.
Forward-Looking Statements
This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy, clinical development of CER-1236, and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo’s management.
Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 2, 2024, and the documents incorporated by reference therein. The risks described in CERo’s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Investors:
CORE IR
investors@cero.bio
FAQ
What are the key findings of CERo Therapeutics' (CERO) preclinical study for CER-1236?
When did CERo Therapeutics present their CER-1236 preclinical data?
What are the potential applications for CERo Therapeutics' (CERO) CER-1236?
